Physician profile
Teagan Perry
NPI 1467134049
$1,951.03
in general payments reported to CMS, 2019-2025
22 companies · $673 in 2025
The $673 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $273 · 2024: $1,006 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $333.70 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $321.95 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $298.09 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.02 | 2023-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $109.58 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $98.75 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Mannkind Corporation | $86.74 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $86.29 | 2023-2025 | Verquvo, Belsomra, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.23 | 2023-2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.99 | 2023-2025 | Caplyta |
| Pfizer INC. | $55.11 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $41.60 | 2023-2024 | Voquezna |
| Axsome Therapeutics, INC. | $38.92 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.64 | 2024 | Jardiance |
| Tolmar, INC. | $18.47 | 2025 | Jatenzo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $17.39 | 2024 | Fanapt |
| Glaxosmithkline, LLC. | $16.63 | 2024 | Trelegy Ellipta, Arexvy |
| Currax Pharmaceuticals LLC | $16.07 | 2023 | Onzetra Xsail, Contrave |
| Teva Pharmaceuticals USA, INC. | $15.83 | 2023 | Austedo Xr |
| Exeltis, USA INC. | $15.80 | 2024 | Slynd |
| Astellas Pharma US INC | $15.66 | 2024 | Veozah |
| Exact Sciences Corporation | $14.57 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teagan Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.